Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 11/20 | 0.64 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.64 |
| ▸ | PGR | P06401 | 5/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.64 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.64 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.64 |
| ▸ | AR | P10275 | 2/20 | 0.64 |
| ▸ | TNF | P01375 | 1/20 | 0.64 |
| ▸ | IL6 | P05231 | 1/20 | 0.64 |
| ▸ | GLUL | P15104 | 1/20 | 0.64 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.64 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | SHBG | P04278 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL1477515 | 1.00 | HIF1A (0.64) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| Succinic Acid SCHEMBL7096415 | 0.97 | HIF1A (0.63) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL2299293 | 0.94 | HIF1A (0.72) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL13270299 | 0.94 | HIF1A (0.72) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL1512721 | 0.94 | HIF1A (0.72) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL719929 | 0.93 | HIF1A (0.70) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| Phosphoric Acid SCHEMBL1237365 | 0.92 | NR3C1 (0.65) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| Phosphoric Acid SCHEMBL1929804 | 0.92 | NR3C1 (0.64) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| Succinic Acid SCHEMBL7600416 | 0.91 | HIF1A (0.66) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| Phosphoric Acid SCHEMBL5501494 | 0.91 | NR3C1 (0.67) | HIF1ANR3C1HSD17B10PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8363 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122005818-A | Application of miR-144 inhibitor in preparation of medicine for enhancing curative effect of glucocorticoid on ARDS and composition thereof | 胜利油田中心医院 | 2026-05-12 | — | — | CN | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-3820479-B1 | METHODS TO REDUCE COMPLICATIONS OF INTRA-ARTICULAR STEROID | TAIWAN LIPOSOME CO LTD (TW) | 2026-03-11 | — | — | EP | claimed |
| US-12472069-B2 | Methods for sacroiliac joint stabilization | Tenon Medical, Inc. (US) | 2025-11-18 | — | — | US | claimed |
| EP-4646441-A1 | ANTI-IL-11R ALPHA ANTIBODIES FOR TREATING THYROID EYE DISEASE | Lassen Therapeutics, Inc. (US) | 2025-11-12 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | QINGDAO HAIJI BIOMEDICINE CO., LTD. (CN) | 2025-07-22 | — | — | US | claimed |
| EP-4580674-A2 | ANTIGEN BINDING MOLECULES TARGETING PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) | Flagship Pioneering Innovations VI, LLC (US) | 2025-07-09 | — | — | EP | claimed |
| EP-4567037-A1 | USE OF PYRROLOPYRIMIDINE COMPOUND IN TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2025-06-11 | — | — | EP | claimed |
| US-5770222-A | Therapeutic drug delivery systems | IMARX PHARMACEUTICAL CORP. (US) | 1998-06-23 | — | — | US | claimed |
| EP-0740528-A4 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP (US) | 1998-04-01 | — | — | EP | claimed |
| US-5733572-A | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles | IMARX PHARMACEUTICAL CORP. (US) | 1998-03-31 | — | — | US | claimed |
| WO-1997020578-A1 | NON-PRESERVED TOPICAL CORTICOSTEROID FOR TREATMENT OF DRY EYE, FILAMENTARY KERATITIS, AND DELAYED TEAR CLEARANCE | UNIVERSITY OF MIAMI (US) | 1997-06-12 | — | — | WO | claimed |
| WO-1997015298-A1 | COMBINATION OF LTD, RECEPTOR ANTAGONISTS WITH GLUCOCORTICOSTEROIDS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-05-01 | — | — | WO | claimed |
| EP-0740528-A1 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP. (US) | 1996-11-06 | — | — | EP | claimed |
| WO-1995015118-A1 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP. (US) | 1995-06-08 | — | — | WO | claimed |
| US-4406883-A | SHAPES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1983-09-27 | — | — | US | claimed |
| US-4292300-A | METHYL CELLULOSE, WATER, DRUG | INVERESK RESEARCH INTERNATIONAL (GB) | 1981-09-29 | — | — | US | claimed |
| US-4265875-A | HYDROXYPROPYL METHYL CELLULOSE | INVERESK RESEARCH INTERNATIONAL (GB) | 1981-05-05 | — | — | US | claimed |